Year Founded
2024
Ownership
Private
Employees
~66
Stage
Preclinical
Modalities
GEMMA Biotherapeutics General Information
Newly formed company focused on gene therapy research and development for rare diseases, launched in October 2024
Drug Pipeline
No pipeline data available
Key Partnerships
Fiocruz, Franklin Biolabs
GEMMA Biotherapeutics Funding
No funding data available
To view GEMMA Biotherapeutics's complete valuation and funding history, request access »
GEMMA Biotherapeutics Investors
Double Point Ventures
Investor Type: Venture Capital
Holding: Minority
Bioluminescence Ventures
Investor Type: Venture Capital
Holding: Minority
Earlybird Venture Capital
Investor Type: Venture Capital
Holding: Minority
You're viewing 3 of 4 investors. Get the full list »